Drugs / pNGVL3-hICD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00436254 | Oct 2001 → Mar 2010 | HER2 positive breast carcinoma, female breast carcinoma, ovarian carcinoma, ovarian germ cell tumor | University of Washington | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pNGVL3-hICD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00436254 ↗ |
| Modality | Vaccine | “This is a dose-escalation study of a plasmid-based DNA (pNGVL3-hICD) vaccine.” NCT00436254 ↗ |
| Target | ERBB2 | “a plasmid-based vaccine encoding the ERBB2 intracellular domain” PMID 36326756 ↗ Jan 2023 |